Premium
Edoxaban prevented adverse effects including pyrexia and elevation of D‐dimer caused by the combination of BRAF and MEK inhibitors in a patient with BRAF‐mutant melanoma
Author(s) -
Mukai Kei,
Kamata Masahiro,
Miyazaki Mirei,
Nagata Mayumi,
Fukaya Saki,
Hayashi Kotaro,
Fukuyasu Atsuko,
Ishikawa Takeko,
Ohnishi Takamitsu,
Tada Yayoi,
Tanaka Takamitsu
Publication year - 2021
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/1346-8138.15813
Subject(s) - dabrafenib , trametinib , medicine , melanoma , adverse effect , concomitant , vemurafenib , mek inhibitor , edoxaban , oncology , pharmacology , cancer research , mapk/erk pathway , metastatic melanoma , kinase , dabigatran , warfarin , biology , microbiology and biotechnology , atrial fibrillation
The combination of BRAF inhibitor and MEK inhibitor is one of the first‐line treatments for unresectable BRAF‐mutant melanoma or as an adjuvant therapy. However, some patients who received the combination of dabrafenib and trametinib (CombiDT) or the combination of encorafenib and binimetinib (CombiEB) had adverse events (AEs) including pyrexia. We herein report a patient with BRAF‐mutated melanoma who repeatedly developed elevated levels of D‐dimer and pyrexia after CombiDT and CombiEB treatments. Moreover, concomitant edoxaban prevented these AEs, enabling the patient to continue receiving CombiEB.